Journal: Journal of Tissue Engineering

Article Title: Engineering transplantable human lymphatic and blood capillary networks in a porous scaffold

doi: 10.1177/20417314221140979

Figure Lengend Snippet: Plated cell types: human cardiac microvascular endothelial cells (hCMEC, PromoCell), hBEC (Lonza HMVEC-dBLAD), hLEC (Cascade HMVECad), and human dermal lymphatic endothelial cells (hDLEC, PromoCell) immuno-stained for hCD31 (left hand panel) podoplanin (middle panel). DAPI: blue nuclei. Corresponding bright field images of CD31 and podoplanin immuno-stained cells appear to the right of each immuno-stained image. The right panel indicates a negative control with DAPI (blue nuclei) staining. Scale bar = 50 µm in each image.

Article Snippet: Sections were overlaid with primary antibody (rabbit polyclonal CD31 antibody, 1:50 Thermo Fisher Scientific), mouse monoclonal podoplanin antibody (clone D2-40, 1:100, Dako), mouse monoclonal smooth muscle actin (clone 1A4, 1:100, Dako) diluted in 5% (v/v) goat serum, overnight at 4°C.

Techniques: Staining, Negative Control

Journal: Materials Today Bio

Article Title: Tissue-engineered small-diameter vascular grafts containing novel copper-doped bioactive glass biomaterials to promote angiogenic activity and endothelial regeneration

doi: 10.1016/j.mtbio.2023.100647

Figure Lengend Snippet: Macroscopic observation, Histological staining (H&E) and Immunofluorescence staining (CD31) of subcutaneously implanted P:P and P:P:Bs grafts. H&E and CD31 staining showing accelerated angiogenesis (arrows) in P:P:B1 and P:P:B2 grafts. Despite high angiogenesis in P:P:B3 graft, the inflammatory response was observed.

Article Snippet: Following overnight incubation at 4 °C with a rabbit polyclonal primary antibody to CD31 (Ab28364, 1:100, Abcam, USA), the samples were incubated with a goat anti-rabbit IgG H&L secondary antibody (1:50, Abcam, USA) at room temperature for 90 min.

Techniques: Staining, Immunofluorescence

Journal: Cell Death & Disease

Article Title: Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation

doi: 10.1038/s41419-022-05251-4

Figure Lengend Snippet: A Schematic representation of in vivo experiments. GFP-positive Caki-1 cells were treated with drugs constantly for 3 weeks. After a 7-day break to increase the cell number, cells were treated for the next 7 days. Next, resistant cells were harvested and mixed with wild-type Caki-1 in a 1:1 ratio and injected subcutaneously into NOD-SCID mice. B Effect of drug resistance on tumor volume (left graph) and tumor weight (right graph). control, N = 18; sunitinib, N = 16; sorafenib, N = 18. C mRNA analysis of lung metastasis using real-time PCR. N = 17 for each group except sorafenib, N = 18. D Representative merged images of bright-field and GFP fluorescence (upper panel) or only GFP fluorescence (lower panel) of tumor sections E Percentage quantification of GFP-positive tumor area to total tumor area in tumor sections, N = 6 control; N = 8 sunitinib; N = 7 sorafenib. F Percentage of tumor-free mice after cancer-cell injection. P value summary ** calculated with Log-rank (Mantel–Cox) test, N = 18 per group. G , H Representative images after immunofluorescence staining of CD31 ( G ) and ICAM-1 ( H ). I CD31 IHC staining of tumor sections and quantification of functional vessels with a visible lumen. J mRNA level of MMP9 and IL8 in tumors, quantified with real-time PCR. IL8 , N = 10 per group, MMP9 , N = 5. K The level of secreted IL8 in mouse plasma obtained using ELISA, N = 8 per group. Tumors were collected 6 weeks after s.c. injection of RCC cells. The results are presented as the mean ± SEM. P values were estimated using One-way ANOVA with post hoc Tukey’s multiple comparison test, except MMP9 where the Student’s t test was used. * P < 0.05; ** P < 0.01.

Article Snippet: IHC evaluation was also performed using primary rabbit polyclonal anti-CD31 antibody (1:50, Abcam) and EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse (DakoCytomation) to visualize tumor vascularization.

Techniques: In Vivo, Injection, Control, Real-time Polymerase Chain Reaction, Fluorescence, Immunofluorescence, Staining, Immunohistochemistry, Functional Assay, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Comparison